Flare Therapeutics Funding Round

6/30/2026

Venture Equity

$85,000,000

Series C

Proceeds from the financing will be used to advance the Company's prioritized programs, as well as for working capital and general corporate purposes.

Private & Independent

Biopharmaceutical

215 First St 150
Cambridge, MA 02142
USA

Flare is lighting up a new therapeutic space with an entirely different approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of our scientific founders, Flare's team is leveraging the power of 'switch sites' as druggable regions that hold the control for predictable and profound changes in DNA transcription, and therefore, gene expression. Our drug discovery to target 'switch sites' has rapidly advanced, resulting in our pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology.